Healthcare >> CEO Interviews >> March 22, 2019

Interview with the President and CEO: SCYNEXIS, Inc. (NASDAQ:SCYX)

Taglietti, Marco
Dr. Marco Taglietti joined SCYNEXIS, Inc. as President and Chief Executive Officer in April 2015 and has been a member of the board since November 2014. He became President of the company in September 2015. He was Executive Vice President, Research and Development, and Chief Medical Officer of Forest Laboratories, Inc. and President of the Forest Research Institute until its acquisition by Actavis in 2014. Earlier, Dr. Taglietti was Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc., a GSK company, for three years. Before, he spent 12 years at Schering-Plough Corporation, where the last position he held was Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. During his career, he has brought to market 35 different products in the U.S. and internationally. Dr. Taglietti is on the board of directors of BioNJ, Inc. and Delcath (NASDAQ:DCTH). He received his medical degree and board certifications from the University of Pavia in Italy. Profile
Word count: 3,951

TWST: Could you give us a brief overview of SCYNEXIS at this time?

Dr. Taglietti: SCYNEXIS is a biotech company focused on developing new